Comparative Immunological Study in Mice of Inactivated Influenza Vaccines Used in the Russian Immunization Program

Shanko, Andrei; Shuklina, Marina A.; Kovaleva, A. A.; Zabrodskaya, Yana A.; Vidyaeva, Inna G.; Shaldzhyan, Aram A.; Fadeev, Artem; Korotkov, Alexandr V.; Zaitceva, Marina; Степанова, Л. А.; Цыбалова, Л. М.; Kordyukova, Larisa V.; Katlinski, Anton

doi:10.3390/vaccines8040756

Cited by 3 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В отличие от нашего исследования, группы животных были небольшими (n = 6); сами животные были трансгенными Tg (K18-hACE2) для изучения АТ-зависимого эффекта; иммунизация вакциной для профилактики гриппа была проведена однократно [11]. В нашем же исследовании мыши линии BALB/c были привиты дважды гриппозной вакциной, как было описано ранее [13].…”

Section: Discussionunclassified

See 1 more Smart Citation

Development of specific immunity in laboratory animals after co-immunization against seasonal influenza and COVID-19

Ignatyev¹,

Leneva²,

Atrasheuskaya³

et al. 2022

Journal of microbiology, epidemiology and immunobiology

View full text Add to dashboard Cite

Introduction. In clinical practice, the differential diagnosis of COVID-19 can be challenging during the flu season, entailing serious consequences such as delays in appropriate control measures against the SARS-CoV-2 pandemic. Another problem is posed by co-infection of SARS-CoV-2 and influenza virus (IV), which significantly contributes to the severity of the COVID-19 disease. This study was aimed to explore the cross-impact of co-administration of Russian influenza and COVID-19 vaccines on development of specific immunity in laboratory animals.Materials and methods. The study was conducted on BALB/c mice. The animals were inoculated intramuscularly with the vaccine for COVID-19 prevention (CoviVac) and the vaccine for influenza prevention (Flu-M). The sera from the immunized animals were examined separately. Three IV strains were used in the hemagglutination inhibition assay. Antibodies (Abs) against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA). The neutralization test was performed to detect virus neutralizing antibodies against SARS-CoV-2 and IV.Results. Relatively high titers of specific Abs were found in the groups of animals inoculated with one vaccine and with two vaccines concurrently. In the groups of animals inoculated with CoviVac and with two vaccines concurrently, both in the ELISA test and in the neutralization test, the average titers of specific Abs against SARSCoV- 2 did not demonstrate any statistical difference. The group of animals inoculated concurrently with two vaccines demonstrated statistically higher titers of Abs against IV after the second immunization compared to the group of animals inoculated with Flu-M.Discussion. The study has shown that post-vaccination immunity both to IV and to SARS-CoV-2 develops after co-vaccination with two vaccines. The observed enhanced post-vaccination immune response to IV in the coimmunized laboratory animals needs further research.Conclusion. The performed studies suggest the possibility of co-administration of two vaccines to prevent influenza and COVID-19.

show abstract

Section: Discussionunclassified

“…Реакцию торможения гемагглютинации (РТГА) проводили в соответствии с протоколом ВОЗ [12] по ранее описанной методике [13]…”

Section: материалы и методыunclassified

Development of specific immunity in laboratory animals after co-immunization against seasonal influenza and COVID-19

Ignatyev¹,

Leneva²,

Atrasheuskaya³

et al. 2022

Journal of microbiology, epidemiology and immunobiology

View full text Add to dashboard Cite

show abstract

“…• Согласно исследованию инактивированных вакцин против гриппа, используемых в Российской национальной программе иммунизации, сравнение различных препаратов показало, что вакцина Ультрикс® Квадри производства ООО «ФОРТ» (Россия) содержит меньшее количество примесей белков клетки-хозяина, демонстрирует хорошую корреляцию между наиболее распространенными вирусными белками, обнаруживаемыми различными методами, и имеет хорошо организованные розетки антигенов, которые могут быть благоприятными для запуска лучшего иммунного ответа [11].…”

Section: позиция воз в отношении вакцинации против гриппа в условиях пандемии Covid-19 [10]unclassified

The actuality of preventing influenza and pneumococcal infection during the ongoing COVID-19 pandemic

Игнатова¹,

Антонов²

2021

View full text Add to dashboard Cite

The article discusses the issues of vaccine prevention of influenza and pneumococcal infections during the ongoing pandemic of the new coronavirus infection COVID-19. Statistical data on the prevalence of these infections at the current time are provided. Co-infection can increase the symptoms of the diseases in these cases, and managing this condition is important for certain groups of patients. Respiratory viruses induce the attachment of pneumococcus, Pseudomonas aeruginosa and Hemophilus bacillus to the epithelial cells of the respiratory tract. The WHO position on influenza vaccination in the context of the COVID-19 pandemic is presented, and its main provisions are analyzed. Recommendations on the use of the main types of vaccines are given. Currently, the priority is to use 4-valent vaccines that ensure the development of the most stable immunity. In the Russian Federation, such a vaccine that meets all WHO recommendations is Ultrix Quadri, a tetravalent inactivated split influenza vaccine. The drug is a mixture of protective surface and internal antigens of influenza viruses of type A [subtypes A(H1N1) and A(H3N2)] and type B (Yamagata line and Victoria line). The use of vaccination schemes for pneumococcal infection was also discussed.

show abstract

Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines

Sergeeva,

Romanovskaya-Romanko,

Krivitskaya

et al. 2023

Vaccines

View full text Add to dashboard Cite

Neuraminidase (NA)-based immunity could reduce the harmful impact of novel antigenic variants of influenza viruses. The detection of neuraminidase-inhibiting (NI) antibodies in parallel with anti-hemagglutinin (HA) antibodies may enhance research on the immunogenicity and duration of antibody responses to influenza vaccines. To assess anti-NA antibodies after vaccination with seasonal inactivated influenza vaccines, we used the enzyme-linked lectin assay, and anti-HA antibodies were detected in the hemagglutination inhibition assay. The dynamics of the anti-NA antibody response differed depending on the virus subtype: antibodies to A/H3N2 virus neuraminidase increased later than antibodies to A/H1N1pdm09 subtype neuraminidase and persisted longer. In contrast to HA antibodies, the fold increase in antibody titers to NA after vaccination poorly depended on the preexisting level. At the same time, NA antibody levels after vaccination directly correlated with titers before vaccination. A difference was found in response to NA antigen between split and subunit-adjuvanted vaccines and in NA functional activity in the vaccine formulations.

show abstract

Comparative Immunological Study in Mice of Inactivated Influenza Vaccines Used in the Russian Immunization Program

Cited by 3 publications

References 42 publications

Development of specific immunity in laboratory animals after co-immunization against seasonal influenza and COVID-19

Development of specific immunity in laboratory animals after co-immunization against seasonal influenza and COVID-19

The actuality of preventing influenza and pneumococcal infection during the ongoing COVID-19 pandemic

Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines

Contact Info

Product

Resources

About